Bravelle (Urofollitropin Injection) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 25, 2012

Bravelle

Infertility »

What is infertility?

Infertility means not being able to get pregnant after one year of trying. Or, six months, if a woman is 35 or older. Women who can get pregnant but are unable to stay pregnant may also be infertile.

Pregnancy is the result of a process that has many steps. To get pregnant:

A woman must release an egg from one of her ovaries (ovulation).
The egg must go through a Fallopian tube toward the uterus (womb).
A man's sperm must join with (fertilize) the egg along the way.
The fertilized egg must attach to the inside of the uterus (implantation).

Infertility can happen if there are problems with any of these steps.

Is infertility a common problem?

Yes. About 10 percent of women (6.1 million) in the United States ages 15-44 have difficulty getting pregnant or staying pregnant, according to the Centers for Diseas...

Read the Infertility article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Bravelle User Reviews >>

Bravelle

Premenstrual Syndrome (PMS) Slideshow Pictures

Take the Menopause Quiz

What's Causing Your Pelvic Pain Slideshow Pictures

font size

OVERDOSE

Aside from possible ovarian hyperstimulation (see WARNINGS) and multiple gestations (see WARNINGS), little is known concerning the consequences of acute overdosage with Bravelle® (urofollitropin injection) .

CONTRAINDICATIONS

Bravelle® (urofollitropin injection) is contraindicated in women who have:

A high FSH level indicating primary ovarian failure.
Uncontrolled thyroid and adrenal dysfunction.
An organic intracranial lesion such as pituitary tumor.
The presence of any cause of infertility other than anovulation.
Abnormal bleeding of undetermined origin.
Ovarian cysts or enlargement not due to polycystic ovary syndrome.
Prior hypersensitivity to urofollitropins, purified.
Bravelle® (urofollitropin injection) is contraindicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of Bravelle® (urofollitropin injection) when administered during pregnancy.